Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population

Mayo Clinic Proceedings

Volumn 87, Issue 6, 2012, Pages 517-523

  Dispenzieri, Angela ^a   Katzmann, Jerry A ^a   Kyle, Robert A ^a   Larson, Dirk R ^a   Therneau, Terry M ^a   Colby, Colin L ^a   Clark, Raynell J ^a   Mead, Graham P ^b   Kumar, Shaji ^a   Melton, L Joseph ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN KAPPA FREE LIGHT CHAIN; IMMUNOGLOBULIN LAMBDA FREE LIGHT CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; CAUSE OF DEATH; CONFERENCE PAPER; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

EID: 84863442192     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.03.009     Document Type: Conference Paper

References (23)

1. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23(2):215-224.
2. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet. 2010;375(9727):1721-1728.
3. Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009;144(2):217-222.
4. Yegin ZA, Ozkurt ZN, Yaǧci M. Free light chain: A novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur J Haematol. 2010;84(5):406-411.
5. Maurer MJ, Micallef IN, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011;29(12):1620-1626.
6. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107(8):3378-3383.
7. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773-779.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
9. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817. (Pubitemid 41076419)
10. Melton LJ III. The threat to medical-records research. N Engl J Med. 1997;337(20):1466-1470.
11. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: The Rochester Epidemiology Project. Am J Epidemiol. 2011;173(9):1059-1068.
12. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71(3):266-274.
13. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437-1444. (Pubitemid 34925779)
14. Compressed Mortality File (CMF), 1989-1998. http://www. cdc.gov/nchs/data-access/cmf.htm. Accessed May 3, 2012.
15. Gail MH, Byar DP. Variance calculations for direct adjusted survival curves, with applications to testing for no treatment effect. Biometric J. 1986;28:587-599.
16. Compressed Mortality File (CMF), 1999-2002. http://www. cdc.gov/nchs/data-access/cmf.htm. Accessed May 3, 2012.
17. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
18. Gottenberg JE, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis. 2007;66(1):23-27. (Pubitemid 46044856)
19. Puntmann VO, Taylor PC, Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: Systemic inflammation and aging-a mini-review. Gerontology. 2011;57(4):295-303.
20. Busse PJ, Mathur SK. Age-related changes in immune function: Effect on airway inflammation. J Allergy Clin Immunol. 2010; 126(4):690-700.
21. Ahmad A, Banerjee S, Wang Z, Kong D, Majumdar AP, Sarkar FH. Aging and inflammation: Etiological culprits of cancer. Curr Aging Sci. 2009;2(3):174-186.
22. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221-233.
23. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. (Pubitemid 36019639)